USPTO grants patent to Vernagen's mRNA-Based RSV A/B Vaccine

- On March 4, 2025, Vernagen, U.S. company of ST Pharm, was successfully granted its mRNA-Based RSV A/B vaccine patent by the USPTO

- Vernagen has developed an mRNA-based vaccine that protects against both RSV (Respiratory Syncytial Virus) and hMPV (Human Metapneumovirus)

- With its enhanced mechanism of action, this vaccine helps protect vulnerable populations and represents a significant advancement in inducing an immune response against emerging viral variants in the future.

[Key Details]

Patent Number : US 12,239,701
Technology Name : RSV mRNA Vaccine
Technology Description : An mRNA vaccine composition designed to induce an immune response against RSV and hMPV, enabling effective immunization.